Next Generation Medicine

Targeted, Full Spectrum RNAi / PSR

NexGen Biomedical, Inc. believes its Targeted, Full Spectrum RNAi / PSR platform technology will set an unbeatable potency standard for RNAi technologies. Combined with its built in targeting solution, and established systemic human safety, it can rapidly be brought to market to establish an unbeatable potency standard for treatment of dermal, pulmonary, and transdermal conditions including Psoriasis, Actinic Keratosis, Herpes Lesions, Acne, COPD, Asthma, Avian Flu, Rheumatoid Arthritis, and Macular Degeneration (Wet).

• Executive Summary (HTML) (PDF)

• Comparison of Antisense RNA, siRNA, and RNAi / PSR (HTML) (PDF)

• Slide Show (PDF)

• Full Product, Clinical, and Patent Data (PDF)

Cancer

Today’s chemotherapy protocols fail to cure the vast majority of cancers. NexGen Biomedical, Inc. has identified the major reasons for this failure and has pursued a solution termed Tumor Specific (TS) Cell Cycle Synchronous Chemotherapy (CCSC). The novel protocols are protected by a series of issued and pending patents. Detailed disclosures are provided in US Patent 7,507,704 (PDF) and in a detailed slide show on Cancer and Chemotherapy.

Summary and Overview Documents are provided below:

• Executive Summary (HTML) (PDF)

• TS - CCSC Full Science and Business Slides (PDF)

Migraines and Seizures
Our latest research has identified a novel etiology underlying migraines and seizures. It finally provides a coherent explanation for all of the disparate symptoms and observations related to most migraines as well as many types of seizures. Accordingly, novel treatment methods are proposed that target the underlying etiology, rather than today’s treatments that target downstream events or symptoms. We currently have patents pending in this area and the website will be updated accordingly.

The Team

Contact Info: Mark Zamoyski, e-mail to:mark@nexgen.biz, Tel: 408-365-1170

DISCLAIMER AND IMPORTANT NOTICE:The Compositions and Methods presented on this website are all in preclinical stages. They are based only on our understanding of the proposed underlying mechanisms of action and on any available coincidental corroborative empirical evidence, any of which may in fact turn out not to be correct, or may be prevented from functioning as envisioned because of other factors or mechanisms of action not contemplated or considered, or may even cause harm because of factors or mechanisms of action not anticipated. The process of obtaining FDA approvals has not been started in any of the areas disclosed on this website. The disclosures here are purely for scientific information exchange purposes, representing one scientific point of view, and are not intended to suggest, or be used for, any proposed medical treatments. NexGen Biomedical, Inc. is a California corporation established in 1999.